Trinity Biotech Stock Rated “Buy” Amid Price Fluctuations
Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...
- Latest
- Trending
Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...
Wedbush lifts Micron's stock target to $170, citing supply shortages and strong financial outlook ahead of Q3 earnings report next ...
Autodesk COO Steven Blum sells shares worth over $3.9M as part of a trading plan; retains 54,136 shares; Autodesk reports ...
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Citi reaffirms Buy on Palo Alto Networks with a $345 target, citing stable FCF conversion and longer contract bookings amidst ...
Deutsche Bank's 3% DCF growth rate signals GDP alignment; Analyst warns Oracle's rating, target price risks. AI-assisted, editor-reviewed. Learn more ...
Nexalin Technology: 0.7% institutional, 7% insider ownership. Beta of 5.13 reveals high volatility; rivals surpass in 8 of 10 factors. ...
Weibo's beta of 0.24 shows lower volatility compared to Trump Media's beta of 6.14. Weibo, founded in 2009, has 3% ...
Nexalin shares are 1% shorted; 52-week range $0.25-$3.40. Market cap: $6.69M, PE ratio: -1.36, beta: 5.13. Qtr EPS: -$0.10; ROE: ...
NaaS Technology (NASDAQ:NAAS) posted Q1 losses with EPS at ($1.40). Laidlaw Wealth Management boosted stakes 242.8% in Q4.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.